Ovarian Cancer

>

Latest News

 Olaparib/Cediranib Combo Misses the Mark in Ovarian Cancer
Olaparib/Cediranib Combo Misses the Mark in Ovarian Cancer

March 16th 2024

Olaparib plus cediranib did not improve survival compared with chemotherapy in patients with platinum-resistant or -refractory epithelial ovarian cancer.

FDA Grants Orphan Drug Designation to Avutometinib in Ovarian Cancer
FDA Grants Orphan Drug Designation to Avutometinib in Ovarian Cancer

March 6th 2024

FDA Clears Clinical Study of Vaccine Therapy for Ovarian Cancer
FDA Clears Clinical Study of Vaccine Therapy for Ovarian Cancer

March 5th 2024

Olaparib Rechallenge Offers PFS Improvements in Ovarian Cancer
Olaparib Rechallenge Offers PFS Improvements in Ovarian Cancer

February 22nd 2024

Shahin Analyzes Benefits of Individualized Dosing With PARP Inhibitors in Advanced Ovarian Cancer
Shahin Analyzes Benefits of Individualized Dosing With PARP Inhibitors in Advanced Ovarian Cancer

February 10th 2024

Video Series
Video Interviews

More News